Comparative Pharmacology
Head-to-head clinical analysis: MACROTEC versus STRONTIUM CHLORIDE SR 89.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACROTEC versus STRONTIUM CHLORIDE SR 89.
MACROTEC vs STRONTIUM CHLORIDE SR-89
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not applicable for diagnostic use.
Strontium-89 is a calcium mimetic that localizes to bone, particularly areas of increased osteoblastic activity, emitting beta radiation that causes DNA damage and cell death in metastatic tumor cells.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
148 MBq (4 mCi) intravenously over 1-2 minutes, single dose. Repeat after 3-6 months if needed.
None Documented
None Documented
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Terminal elimination half-life: 50.5 days (range 33–65 days). Reflects slow clearance from bone; clinical effect persists due to long skeletal retention.
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Primarily renal (urinary) excretion; approximately 50-80% of absorbed dose eliminated via urine over 7 days. Fecal elimination is negligible (<5%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical